BridgeBio Pharma Shares Positive Long-Term Data on LGMD2I/R9 Study Overview Early assessment of increased glycosylated ⍺DG levels at 3 months predicted subsequent ambulatory improvements at 9 months, supporting the use of glycosylated ⍺DG levels as a potential surrogate endpoint in LGDM2I/R9. Long-term data from the ongoing Phase 2 study of BBP-418 in patients with LGMD2I/R9…

Welcome to the Future of South Africa E-Commerce! Get ready to dive into a world of endless possibilities… Have you heard the latest news? The South Africa E-Commerce market is estimated to be valued at a whopping US$ 6.2 billion in 2023, and that’s just the beginning! According to the experts at RationalStat, this rapidly…

The beginning of the week is marked by heightened risk aversion and increasing geopolitical uncertainties Escalating conflicts in the Middle East As the new week kicks off, the global financial markets are grappling with heightened risk aversion and escalating geopolitical uncertainties, with the primary focus on the situation in the Middle East. The region has…

Welcome to the Wonderland of Investment News! Delve into the Important Oct 30 Lead Plaintiff Deadline for NAPCO Security Technologies, Inc. Investors Hey there, fellow investors! Are you keeping an eye on NAPCO Security Technologies, Inc. (NASDAQ: NSSC)? If not, it’s time to pay attention because there’s some juicy news you won’t want to miss….

Welcome to our Blog DLocal Limited Investors Alert October 6, 2023 Robbins Geller Rudman & Dowd LLP has announced that investors who purchased or acquired DLocal Limited (NASDAQ: DLO) securities between May 2, 2022 and May 25, 2023, may be eligible to participate in the DLocal class action lawsuit. Investors have until December 5, 2023…